What is the expected mortality rate for a patient with a Model for End-Stage Liver Disease (MELD) score of 33?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mortality Risk for MELD Score 33

A MELD score of 33 is associated with approximately 52.6% mortality risk at 90 days without liver transplantation. 1

MELD Score and Mortality Risk Correlation

The Model for End-Stage Liver Disease (MELD) score is a validated tool for predicting short-term mortality in patients with end-stage liver disease. For a MELD score of 33, the evidence indicates:

  • MELD scores in the range of 30-39 correlate with a 52.6% mortality risk at 90 days 1
  • Higher MELD scores predict significantly worse outcomes, with mortality increasing proportionally with the score 2
  • Patients with MELD scores >30 require careful evaluation for liver transplantation due to their high mortality risk 1

Clinical Implications of MELD 33

A MELD score of 33 has several important clinical implications:

  • It exceeds the threshold of 30.5 that the American Gastroenterological Association recommends as a fixed cut-off value for predicting the need for liver transplantation 3
  • It represents severe liver dysfunction with poor short-term prognosis without intervention 1
  • The 3-month mortality for patients with MELD scores between 18-24 is approximately 35%, and for scores ≥25, it rises to 66% 3

MELD Score Components and Mortality Risk

The mortality risk associated with a MELD score of 33 may vary depending on which component is driving the elevated score:

  • MELD-Cr subtype (creatinine-dominant) has worse one-year intent-to-treat survival (65%) compared to MELD-Br (bilirubin-dominant, 78%) or MELD-INR (75%) subtypes 4
  • Patients with kidney dysfunction as the primary driver of their high MELD score have higher waitlist mortality and lower liver transplantation rates 4

Transplantation Considerations

For patients with a MELD score of 33:

  • Liver transplantation should be strongly considered as the definitive treatment 1
  • The high mortality risk without transplantation (>50% at 90 days) must be weighed against potential post-transplant outcomes 2
  • Despite the high MELD score, post-transplant survival can be comparable to those with lower MELD scores (35-39) 2

Monitoring and Management

For patients with a MELD score of 33:

  • Close monitoring is essential due to the high risk of rapid deterioration 1
  • Serial MELD score calculations help track disease progression and prioritize for transplantation 5
  • Multidisciplinary assessment including hepatologist, transplant surgeon, and intensivist is crucial 1

Pitfalls and Caveats

  • MELD score fails to predict mortality in approximately 15% of patients with end-stage liver disease 6, 7
  • The score may not fully capture the severity of certain complications of cirrhosis, such as hepatic encephalopathy or ascites 1
  • Incorporating additional parameters like serum sodium, albumin levels, or APACHE II scores may improve prognostic accuracy 6
  • Female patients may have worse outcomes than males with the same MELD score, particularly in the creatinine-dominant subtype 4

The evidence clearly demonstrates that a MELD score of 33 represents a critical level of liver dysfunction with a mortality risk exceeding 50% at 90 days, necessitating urgent consideration for liver transplantation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.